Venture Capital Investment | Plutus Investment Group
MPC Therapeutics has announced the commercial launch of *MitoStem™* , its first ex vivo metabolic enhancer designed specifically to improve the performance of CAR-T and other engineered cell therapies. What this means: - *MitoStem™* is an ex vivo reagent aimed at increasing the proportion of durable, stem-like T cells, which can improve persistence and expansion of CAR-T therapies, a key driver of clinical efficacy and long-term response in patients. - The product’s launch marks MPC Therapeutics’ transition from R&D into commercial deployment, broadening its value proposition in the rapidly growing cell and gene therapy space. - This follows the company’s recognition as a leading European biotech and complements peer-reviewed work validating metabolic reprogramming strategies to enhance T-cell function. This represents an important milestone in MPC Therapeutics’ growth trajectory and underscores its potential to impact CAR-T manufacturing and therapeutic performance across oncology and beyond.
We are pleased to share a recent milestone from Oxford Cancer Biomarkers (OCB), a University of Oxford spin-out and a portfolio company of Plutus Investment Group LLP. OCB has announced the expanded clinical utility of its proprietary ToxNav® test, strengthening its ability to predict chemotherapy-related toxicity and support safer, more personalised cancer treatment. This development follows a Licence of Technology agreement with Oxford University Innovation, enabling OCB to extend its intellectual property and broaden the clinical application of ToxNav® beyond existing standards of care. With strong academic foundations, validated clinical relevance, and growing international adoption, OCB continues to demonstrate the type of high-impact, precision-medicine innovation we seek to support at Plutus.
"We believe advances like this represent the future of oncology — where data, genetics, and clinical insight converge to improve outcomes at scale."
